cancers-logo

Journal Browser

Journal Browser

Advances in Electroporation-Based Technologies for Cancer Treatment

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Methods and Technologies Development".

Deadline for manuscript submissions: 31 July 2026 | Viewed by 1204

Special Issue Editors


E-Mail Website
Guest Editor
1. Department of Experimental Oncology, Institute of Oncology Ljubljana, 1000 Ljubljana, Slovenia
2. Biotechnical Faculty, University of Ljubljana, 1000 Ljubljana, Slovenia
Interests: combining radiotherapy with immune gene therapy; electroporation-based treatments

E-Mail Website
Guest Editor
1. Department of Experimental Oncology, Institute of Oncology Ljubljana, 1000 Ljubljana, Slovenia
2. Faculty of Health Sciences, University of Ljubljana, 1000 Ljubljana, Slovenia
Interests: tumor biology; electroporation-based treatments
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Electroporation-based technologies are changing the landscape of cancer therapy by enabling the precise local delivery of therapeutic molecules into tumors. Electrochemotherapy has become a clinically established modality for the treatment of cutaneous and subcutaneous malignancies, while non-thermal irreversible electroporation offers a unique approach for the ablation of deep-seated tumors without thermal damage. Gene electrotransfer extends this platform by enabling the local expression of therapeutic genes, including immunostimulatory cytokines such as interleukin-12. Clinical trials in melanoma and head and neck cancer have demonstrated both safety and antitumor activity. Despite these advances, the optimization of delivery protocols, enhancement of the immune response, and translation from local to systemic effects remain an ongoing challenge.

This Special Issue will focus on the pre-clinical and clinical innovative research and translational advances that could help electroporation-based cancer therapies achieve broader clinical application.

Dr. Bostjan Markelc
Prof. Dr. Gregor Sersa
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • electroporation
  • electrochemotherapy
  • gene electrotransfer
  • interleukin-12
  • DNA vaccination
  • irreversible electroporation
  • cancer immunotherapy
  • tumor ablation

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

20 pages, 6127 KB  
Article
Potentiation of Electrochemotherapy by Anti-PD-1 Immunotherapy in Murine Tumors with Distinct Immune Profiles
by Masa Omerzel, Simona Kranjc Brezar, Ursa Lampreht Tratar, Tanja Jesenko, Barbara Lisec, Gregor Sersa and Maja Cemazar
Cancers 2026, 18(1), 90; https://doi.org/10.3390/cancers18010090 - 27 Dec 2025
Cited by 2 | Viewed by 850
Abstract
Background: Electrochemotherapy (ECT) is a clinically validated local ablative treatment increasingly recognized for its ability to induce immunogenic cell death and stimulate antitumor immunity. Its combination with immune checkpoint inhibitors, such as anti-PD-1 antibodies, may enhance systemic immune responses and improve therapeutic [...] Read more.
Background: Electrochemotherapy (ECT) is a clinically validated local ablative treatment increasingly recognized for its ability to induce immunogenic cell death and stimulate antitumor immunity. Its combination with immune checkpoint inhibitors, such as anti-PD-1 antibodies, may enhance systemic immune responses and improve therapeutic efficacy, particularly in poorly immunogenic tumors. Methods: We evaluated the antitumor effectiveness of ECT combined with a murine analog of the anti-PD-1 antibody in four syngeneic murine tumor models with differing histology and immune status: WEHI fibrosarcoma, CT26 and MC38 colorectal carcinoma, and 4T1 mammary carcinoma. In vitro cytotoxicity assays assessed tumor cell sensitivity to ECT, while in vivo experiments evaluated complete response (CR) rates, immune cell infiltration, and long-term immune memory through secondary tumor challenge. Immunohistochemical analysis of CD4+, CD8+, and granzyme B+ effector cells. Results: In vitro, WEHI cells exhibited the highest sensitivity to ECT. In vivo, ECT monotherapy induced CRs in 100% of WEHI tumors, 60% of CT26, 17% of 4T1, and 15% of MC38. The addition of anti-PD-1 significantly enhanced outcomes in less responsive models, increasing CRs to 90% in CT26, 91% in MC38, and 53% in 4T1. Combination therapy promoted pronounced infiltration of CD4+, CD8+, and granzyme B+ T cells and the formation of tertiary lymphoid structure, particularly in MC38 tumors. Secondary challenge experiments confirmed long-term immune memory in CT26 and MC38 models and induced memory in 4T1, which was absent following monotherapy. Conclusions: ECT synergizes with PD-1 blockade to potentiate local and systemic antitumor immunity, overcoming immune resistance in poorly immunogenic tumors. These findings support further clinical development of ECT in combination with immune checkpoint inhibitors as a component of personalized cancer immunotherapy. Full article
(This article belongs to the Special Issue Advances in Electroporation-Based Technologies for Cancer Treatment)
Show Figures

Graphical abstract

Back to TopTop